+ T cells provide cross-protection across seasonal IAVs 9,10 or IBVs 11 and pandemic [12] [13] [14] [15] and avian [16] [17] [18] IAVs by recognizing conserved virusderived peptides presented by major histocompatibility complex class-1 (MHC-I) glycoproteins (human leukocyte antigens; HLAs) on the surface of infected cells. So far, 195 CD8 + T cell epitopes restricted by 24 different HLA allotypes have been identified for IAVs, 7 epitopes (restricted by HLA-A*02:01 or HLA-B*08:01) for IBV and no T cell epitopes for ICV (Immune Epitope Database; accessed 2 January 2018). After recognition of the peptide-MHC-I complex, CD8
A lthough 2018 marked the 100th anniversary of the catastrophic Spanish influenza pandemic, influenza viruses remain a constant, global health threat. Three types of influenza viruses infect humans: type A (influenza A virus; IAV), type B (IBV) and type C (ICV). Two IAV subtypes (A/H3N2 and A/H1N1pdm09) and two IBV lineages (B/Yamagata/16/88-like and B/Victoria/2/87-like) co-circulate annually, causing seasonal epidemics of mild, severe or fatal respiratory disease, whereas ICV causes severe disease in children [1] [2] [3] [4] [5] . Antigenically novel IAVs generated by reassortment of the segmented genome and derived from animal reservoirs can also infect humans with high rates of morbidity and mortality 1 .
The search for a long-lasting, universal, broadly protective vaccine against influenza viruses is ongoing. Immune protection against influenza is mainly mediated by adaptive humoral and cellular responses 1, 2 . Antibodies induced by seasonal inactivated influenza vaccine typically provide strain-specific immunity by targeting the variable head domain of the surface glycoprotein hemagglutinin. Although these antibodies can provide neutralizing immunity, the constant antigenic drift of hemagglutinin makes them poor targets for cross-protection. Broadly cross-reactive antibodies predominantly targeted to the conserved stem of hemagglutinin or at neuraminidase 6 can provide heterosubtypic cross-reactivity across multiple IAV subtypes 7 or across IBVs, but not heterotypic
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Articles NATure ImmuNOLOgy cross-reactivity across IAVs and IBVs, with the exception of one rare antibody clone (CR9114) 8 . Conversely, cytotoxic CD8 + T cells provide cross-protection across seasonal IAVs 9, 10 or IBVs 11 and pandemic [12] [13] [14] [15] and avian [16] [17] [18] IAVs by recognizing conserved virusderived peptides presented by major histocompatibility complex class-1 (MHC-I) glycoproteins (human leukocyte antigens; HLAs) on the surface of infected cells. So far, 195 CD8 + T cell epitopes restricted by 24 different HLA allotypes have been identified for IAVs, 7 epitopes (restricted by HLA-A*02:01 or HLA-B*08:01) for IBV and no T cell epitopes for ICV (Immune Epitope Database; accessed 2 January 2018). After recognition of the peptide-MHC-I complex, CD8
+ T cells kill virally infected cells and release antiviral cytokines (interferon-γ (IFN-γ) and tumor necrosis factor (TNF)). The breadth of CD8 + T cell cross-reactivity across antigenically novel viruses renders these cells promising targets for a universal vaccine. However, the current inactivated influenza vaccine formulation does not boost CD8 + T cells 19 . Thus, new vaccines are needed to harness the potential of cross-protective CD8 + T cells. The establishment of universal immune memory against influenza viruses requires prior knowledge of conserved antigenic regions to facilitate immunogen design and assessment of immune responses. Although antibodies can be first isolated from serum and used to map the epitopes, identification of antigen-specific CD8 + T cells requires prior knowledge of the antigenic epitopes, including both peptides and restricting HLAs. This can inform the antigenic composition of T cell-based vaccines to focus the immune response towards conserved and protective epitopes. Here, we defined the CD8 + T cell cross-reactome against influenza A, B and C viruses, and identified novel IBV CD8 + T cells using immunopeptidomics 20, 21 . We demonstrated that CD8 + T cells confer previously unrecognized, broad heterotypic cross-reactivity and characterized these responses in depth. Our data provide new insights into universal CD8
+ T cells across IAVs, IBVs and ICVs, and suggest that combining universal CD8 + T cells with B cell-based vaccines might lead to a broadly protective influenza vaccine that does not require annual reformulation.
Results
Universal CD8
+ T cell epitopes across IAV, IBV and ICV. To investigate the breadth of CD8 + T cell cross-reactivity across IAVs, IBVs and ICVs, we first assessed the conservation of previously identified IAV-specific CD8 + T cell epitopes across IAVs, IBVs and ICVs ( Fig.  1a and Supplementary Fig. 1 ), as IAV-specific CD8 + T cells have been our the research focus so far. Our conservation analysis of >67,000 influenza segment sequences identified 31 conserved epitopes (with >70% amino acid identity) across IAV and IBV, and 8 epitopes across IAV, IBV and ICV types (Supplementary Table 1 ). Based on the prevalence of HLA-restricting molecules in the population and the nature of alterations within the peptide variants, we selected nine epitopes across both HLA-A (HLA-A*01:01, HLA-A*02:01 and HLA-A*03:01/A*11:01/*31:01/A*68:02) and HLA-B (HLA-B*07:02, HLA-B*44:02 and HLA-B*37:01) alleles (Table 1) for further investigation.
To determine CD8 + T cell immunogenicity towards these epitopes, we probed memory CD8 + T cells within peripheral blood mononuclear cells (PBMCs) obtained from healthy adults using in vitro peptide expansion and measured IFN-γ after peptide restimulation. Three (A1-PB1 591 , n = 3; A2-PB1 413 , n = 5; B37-NP 338 , n = 3) of nine conserved CD8 + T cell epitopes recalled memory responses across multiple donors (Fig. 1b) . These conserved CD8 + T cell peptides (PB1 591-599, PB1 [413] [414] [415] [416] [417] [418] [419] [420] [421] and NP [338] [339] [340] [341] [342] [343] [344] [345] ) are restricted by three prominent HLA molecules (HLA-A*01:01, HLA-A*02:01 and HLA-B*37:01, respectively), providing broad global coverage as ~54% of the population carry at least one of these alleles.
The NMLSTVLGV PB1 413-421 peptide in IAV (positioned as PB1 [414] [415] [416] [417] [418] [419] [420] [421] [422] in IBV and ICV; referred to as PB1 413 hereafter) was universally (>98% of sequences) conserved (>99.9%) across IAV, IBV and ICV, but not in influenza D viruses, where a L7F alteration was found, or in other genera of the Orthomyxoviridae family (Fig. 1c) . The PB1 413-421 peptide has been reported as an IAV epitope 22, 23 shared in sequence with IBV 24 , however CD8 + T cell cross-reactivity has not been shown. To demonstrate the ability of HLA-A2-PB1 413 -specific CD8 + T cells to confer cross-reactivity across IAV, IBV and ICV, PBMCs obtained from HLA-A*02:01-expressing donors were stimulated in vitro with autologous PBMCs infected with IAV, IBV or ICV, followed by measurement of A2-PB1 413 + CD8 + T cells by IFN-γ on day 10 (n = 5) (Fig. 1d) . In contrast to minimal IFN-γ production toward PB1 413 directly ex vivo (Fig. 1d) , ten-day culture with IAV-, IBV-or ICV-infected targets markedly increased the magnitude of A2-PB1 413 -specific CD8 + T cells (Fig. 1d) , owing to expansion of A2-PB1 413 + CD8
+ T cells towards all IAV, IBV and ICV. Our data thus provide evidence that memory A2-PB1 413 + CD8 + T cells are activated after stimulation with IAV-, IBV-or ICV-infected targets, suggesting that CD8
+ T cells can exhibit universal cross-reactivity across IAV, IBV and ICV, and hence have a much broader cross-reactivity potential than has been previously thought.
Analysis of the remaining two conserved and immunogenic peptides (PB1 591-599 and NP 338-345 in IAV; BPB1 590-598 and BNP 394-401 in IBV) revealed variations at 1-2 amino acids (S2A and L8I for PB1 591 and F1Y within NP 338 ) between IAV and IBV, and a lack of conservation in ICV (Table 1) . In vitro expansion with either IAV-or IBV-derived peptides showed unidirectional cross-reactivity, with IAV-expanded CD8 + T cells recognizing both IAV-and IBV-derived peptides. However, the IBV variants could not expand the number of CD8 + T cells directed at the cognate peptides, suggesting lower immunogenicity of these variants (Fig. 1e,f) .
Collectively, our data demonstrate that human CD8 + T cells can confer heterotypic cross-reactivity across IAV, IBV and ICV. As the findings are based on the currently known IAV-derived epitopes and thus limited to IAV peptides, such universal cross-reactivity might be broader than defined here. Furthermore, our data suggest a need for identification of novel CD8 + T cell epitopes recognizing both IAV-and IBV-derived peptides that are restricted by a broad range of HLAs represented across different ethnicities.
Identification of novel HLA-A*02:01-restricted IBV epitopes. As there is a general lack of CD8 + T cell epitopes for clinically relevant and understudied IBVs, we identified novel CD8 + T cell epitopes derived from IBV viruses and presented by HLA-A*02:01, owing to the high global prevalence of this allele. We used immunopeptidomics to define peptides naturally processed and presented on the surface of IBV-infected cells. Epstein Barr virus-transformed B lymphoblastoid class I-reduced (C1R) cell lines stably expressing high levels of HLA-A*02:01 were used, together with parental C1R cells expressing background levels of HLA-B*35:01 and HLA-C*04:01 (ref. 25 ), to exclude peptides derived from these HLAs. Infection of C1R cells with the B/Malaysia strain resulted in high infection rates (~70% BNP + cells) and cell viability (~93%) (Supplementary Fig. 2a ). Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of peptides isolated from HLA-A*02:01 revealed predominantly 9-mer (n = 1,490) peptides, followed by 11-mer (n = 695) and 10-mer (n = 589) peptides (Fig. 2a,b and Supplementary  Fig. 2b ). These peptides exhibited canonical anchor residues of HLA-A*02:01 ligands (leucine at P2 and leucine or valine at the C terminus 26 ; Fig. 2b ). Length distributions were similar for human peptides from uninfected cells and human or viral peptides from infected cells (Fig. 2c and Supplementary Fig. 2c ). Analyses from two experiments yielded 73 potential HLA-A*02:01-presented IBV-derived peptides, with ~64% overlap between experiments (Supplementary Table 2 ). The IBV-derived peptides originated from hemagglutinin (BHA) (22.3%), followed by BNP (16.4%)
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NATure ImmuNOLOgy and BM1 (11.9%), with all IBV proteins contributing to the HLA-A*02:01 immunopeptidome, except BM2 and NB (Fig. 2d) . In contrast, peptides from BM2 were identified with high confidence as HLA-II ligands ( Supplementary Fig. 2d and Supplementary Table 2 ). Of 73 HLA-A2-binding IBV peptides, 67 were synthesized for further investigation. 
CD8
+ T cell responses measured directly ex vivo by ICS are shown for comparison. Representative concatenated FACS plots for IFN-γ production are shown. Data points indicate individual donors, median and IQR (n = 6 from two independent experiments). Statistical significance was determined using two-tailed Wilcoxon matched-pairs signed-rank test, *P < 0.05, **P < 0.005. e,f, B37-NP 338-345 -mediated (e) and A1-PB1 591-599 -mediated (f) cross-reactivity across IAV and IBV. On about day 10 of peptide culture, CD8
+ T cell responses to either IAV or IBV variants were assessed by ICS. Dots indicate individual donors (n = 3 for B37-NP 338 and n = 4 for A1-PB1 591 from one experiment). d-f, 'No peptide' control was subtracted. d, *P = 0.049, **P = 0.0099.
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Novel IBV BHA 543 + and BNS1 266 + CD8 + T cell epitopes in humans. To dissect IBV-specific CD8 + T cells toward the 67 LC-MS/ MS-identified IBV peptides, we probed memory CD8
+ T cell pools in HLA-A*02:01-expressing individuals. We assigned peptides to six pools of 10-12 peptides, avoiding overlapping peptides in the same pool. We established CD8
+ T cell lines for each of the six peptide pools, and then re-stimulated each T cell line with the cognate pool in an IFN-γ and ΤΝF intracellular cytokine staining (ICS) assay (Fig. 2e,f) . CD8
+ T cell responses were predominantly targeted towards pool 2 (80% of donors, n = 11), with smaller responses detected for pools 1, 3, 4 and 6 ( Fig. 2e and Supplementary Fig. 3a) . Dissection of pool 2 identified A2-BHA 543-551 as the prominent epitope among HLA-A*02:01 + donors (n = 6) (Fig. 2g) . Smaller responses towards A2-BHA 538-551 , A2-NS1 266-274 , A2-BNS1 264-274 and BM1 132-140 were detected in some donors ( Supplementary Fig. 3b ). To validate these responses independently, we established CD8 + T cell lines towards individual immunogenic peptides. CD8 + T cell responses to A2-BHA 543-551 were of the greatest magnitude (median 7.35%; n = 6) and more frequent among donors (6 of 6) than A2-NS1 266-274 and A2-BM1 132-140 (0.035% and 0.025%, respectively) ( Fig. 2h and Supplementary Fig. 3b) . Thus, our analysis identified five novel peptides recognized by CD8 + T cells in complex with HLA-A*02:01, with BHA 543-551 being most prominent.
Having identified novel IBV CD8 + T cell epitopes, we determined the conservation of the most prominent peptides, BHA 543-551 and BNS1 266-274 , across IBVs. Both peptides were highly conserved at >98% in >14,000 sequences per segment, spanning both lineages and 77 years (Supplementary Fig. 3c ). Although peptides identified by immunopeptidomics were highly conserved (>70%) in IAV (n = 6 peptides) or in ICV (n = 1) ( Supplementary  Fig. 3d ), these were not immunogenic.
Overall, immunopeptidomics identified 73 novel IBV-derived HLA-A*02:01 peptide ligands. We tested 67 for immunogenicity; CD8 + T cell responses were targeted predominantly to BHA 543-551 , and highly conserved across IBV, but not IAV or ICV. (Fig. 2i) . Conversely, the universal A2-PB1 413 epitope within IBV-specific lines was immunodominant (0.3%; detected in 8 of 11 donors) over the IBV-specific A2-BHA 543 (0.11%; detected in 10 of 11 donors) and A2-BNS1 266 epitopes (0.01%) (Fig. 2j ). These data demonstrate that (1) the universal A2-PB1 413 and the newly identified IBV-specific A2-BHA 543 and A2-BNS1 266 CD8
Universal
+ T cells can be expanded in number after virus stimulation in vitro, and (2) immunodominance of the universal A2-PB1 413 epitope depends on influenza type.
Universal PB1 413
+ CD8 + T cells recruited during human IAV and IBV infection. To evaluate the recruitment and activation of universal A2-PB1 413-421
+
CD8
+ T cells during influenza virus infection, we analyzed PBMCs from three clinical cohorts of PCR-confirmed IAV-or IBV-infected pediatric and adult individuals (Fig. 3) . Using tetramer-associated magnetic enrichment (TAME), we detected influenza-specific CD8 + T cells directly ex vivo in IAV-and IBVinfected pediatric and adult subjects (Fig. 3a,b ) [27] [28] [29] . A healthy adult cohort and HLA-A*02:01-positive subjects hospitalized with a noninfluenza respiratory illness (influenza-PCR negative) were analyzed for comparison (Fig. 3b) . A2-M1 58 -and A2-PB1 413 -specific CD8 + T cells were detected in 100% and 50% of IAV + individuals (n = 16), respectively, whereas A2-BHA 543 -and A2-PB1 413 -specific CD8 + T cells were detected in 75% and 87.5% of IBV + individuals, respectively (n = 8). The frequency of A2-M1 58 -and A2-PB1 413 -specific CD8 + T cells in the blood was significantly increased (4.3-and 6-fold increase, respectively) in IAV-infected subjects as compared to memory CD8 + T cells in healthy donors (Fig. 3c ). The numbers of A2-BHA 543 -and A2-PB1 413 -specific CD8 + T cells in IBV-infected subjects increased 2.2-and 2.6-fold, respectively, above the healthy donors, however these increases did not reach statistical significance, most probably owing to the differential age distribution in IBV-infected, but not IAV-infected, subjects compared to healthy controls. In influenza-negative hospitalized subjects, CD8
+ T cells for three specificities were in the same range as for the healthy donors (Fig. 3c) . Notably, tetramer + CD8 + T cells for all specificities were detected across all age groups (Fig. 3d) .
Tetramer-positive A2-PB1 413
, IBV-A2-BHA 543 + and IAV-A2-M1 58 + CD8 + T cells detected in IAV-or IBV-infected subjects displayed increased CD38
+ and Ki-67 + expression ( Fig. 3e and Supplementary Fig. 4 ), representing an activated phenotype 
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during human viral infections [30] [31] [32] . This suggests that they are recruited during influenza virus infection. This was not observed in the influenza-negative cohort, indicating that this activation is influenza-specific. Upregulation of additional activation markers, HLA-DR and PD-1, was also increased on tetramer Fig. 5 ). The observed variability in numbers and + T cells in healthy and influenza-infected individuals. a, Ex vivo TAME on PBMCs from healthy and infected donors. Representative FACS plots are shown. b, Characteristics of healthy and influenza-infected or influenza-negative influenza-like illness (ILI) cohorts used in this study. c, Precursor frequency of tetramer + cells in healthy controls (HC), influenza-infected individuals and influenza-negative ILI subjects (n = 6 for flu-negative (flu-neg.) ILI, n = 8 for IBV and n = 24 for IAV, assessed over at least two independent experiments). Data points for flu-negative ILI were pooled across CD8 + T cell specificities owing to their varying detection levels across the six donors (5 of 6 for A2-M1 58 , 2 of 6 for A2-PB1 413 and 1 of 6 for A2-BHA 543 ). Statistical significance was determined using a two-tailed Mann-Whitney test, *P = 0.03, **P = 0.0037. Median and IQR are shown. d, Precursor frequency of tetramer + CD8 + T cells in healthy and influenza-infected individuals across age. e, Expression profiles of tetramer + CD8 + T cells for activation markers CD38 and Ki-67. Representative FACS plots are shown. Frequency of CD38 + Ki-67 + tetramer + CD8 + T cells from healthy controls (n = 3-5) and influenzainfected donors (n = 6 for flu-negative ILI, n = 8 for IBV and n = 24 for IAV, assessed over at least two independent experiments). Statistical significance for changes in the frequency of CD38 -Ki-67 -cells was determined using a two-tailed Mann-Whitney test A, *P = 0.017, **P = 0.0025, ## P = 0.0095.
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NATure ImmuNOLOgy phenotype is probably due to (1) the donors' age range and exposure history and (2) varying times of sampling after influenza virus infection (Fig. 3b) . Indeed, CD8 + T cell responses after human influenza A pandemic H1N1 infection peak within 7 d and then contract rapidly 33 . Additionally, the magnitude and activation status of peripheral CD8 + T cells can underrepresent virus-specific cells at the site of respiratory infections 31 . These data show that A2-PB1 413
+ T cells are universal and can be detected with an activated phenotype in HLA-A*02:01-expressing influenza-infected subjects following either IAV or IBV. Additionally, activated CD8 + T cells specific for A2-BHA 543-551 , the epitope identified by immunopeptidomics, can be detected during IBV infection, illustrating the ability of mass spectrometry to identify novel peptide ligands.
Tissue-resident memory universal PB1 413
+ CD8 + T cells in human lungs. As human memory CD8 + T cells also reside outside the blood circulation [34] [35] [36] , we used rare human lung samples from deceased HLA-A*02:01-expressing organ donors (n = 5) to assess the presence of universal A2-PB1 413 +
CD8
+ T cells at the site of infection. We also used human spleens (n = 11), tonsils (n = 4) and lymph nodes (n = 4) to assess the presence of influenza-specific CD8 + T cells in the secondary lymphoid organs (SLOs), where memory CD8 + T cells are enriched. CD8 + T cells specific for A2-M1 58 (4 of 5), A2-PB1 413 (2 of 5), and A2-BHA 543 (1 of 5) were detected within human lung (Fig. 4a) Single-cell RNA analysis of universal and IBV CD8 + T cells. To further understand the recruitment and activation of universal and novel IBV-specific CD8 + T cells during influenza virus infection, we used single-cell RNA sequencing (scRNA-seq) to assess the transcriptome of ex vivo-isolated tetramer +
+ T cells from longitudinal PBMC samples obtained from an IBV-infected HLA-A*02:01-expressing individual. Infection with a B/Victoria strain was confirmed by PCR 37 and serological analysis ( Supplementary  Fig. 6a,b) . Blood samples were obtained at baseline (~3 months 
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CD8
+ T cells were 
+ T cells were assessed at all time points, whereas IBV-specific A2-BHA 543
+ T cells were analyzed on day 14.
A total of 209 tetramer + CD8 + T cells were analyzed using scRNAseq, with ~1,201 expressed genes identified per cell. Principal component analysis revealed clear segregation of A2-PB1 413 + CD8 + T cells by time point but no segregation between the two antigenic specificities on day 14 (Fig. 5c) . Notably, differential expression analysis identified distinct gene expression signatures across time points (Fig. 5d) . Gene-set enrichment analysis showed that signatures of T cell activation and differentiation, cell division, immune cell migration and chemotaxis were enriched in day 14 cells as compared to those from baseline or 1.5 years (Fig. 5e,f) .
We next analyzed the expression of specific genes associated with T cell differentiation, activation, cytotoxicity and effector function ( Supplementary Fig. 6c,d) . Importantly, effector CD8
+ T cells across both IBV specificities isolated from day-14 upregulated genes associated with activation, cytotoxic molecules, cytotoxic receptors and effector cytokines. The expression profiles for selected genes associated with differentiation and activation were confirmed by flow cytometry (Supplementary Fig. 6c,d) .
Although single-cell RNA-seq data were obtained from one subject naturally infected with IBV, this experiment provided a rare opportunity to examine baseline PBMC samples from a HLA-A*0201-expressing subject before natural IBV infection, at the acute (day 14), short-term memory (3 months) and long-term memory (1.5 years) time points after IBV. Our results provide evidence of transcriptome changes associated with differentiation and activation of A2-PB1 413 +
+ and A2-BHA 543 + CD8 + T cells during IBV infection. To the best of our knowledge, these are the first data on transcriptome changes within tetramer-specific CD8
+ T cells at the single-cell level from the baseline to long-term memory CD8 
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NATure ImmuNOLOgy (A2-PB1 413 ) and novel IBV-specific (A2-BHA 543 ) epitopes during influenza in humans, we subsequently investigated the protective efficacy of these cells, especially as the role of CD8 + T cells in IBV infection remains unclear. To achieve this, we used HLA-A2.1-expressing transgenic (HHD-A2) mice previously used for IAV infection 38 , and established a HHD-A2 mouse model of IBV and + T cells responses on days 6 and 7 after infection in BAL and spleen. b, Representative FACS plots. c, Number of total (A2-BHA 543 and A2-BNS1 266 ) tetramer + CD8 T cells in the spleen on day 7 after IBV infection. d, Number of individual A2-BHA 543 + and A2-BNS1 266 + tetramer + CD8 + T cells in the spleen and BAL on days 6 (D6) and 7 (D7) after IBV infection. e, Viral titers in lungs and nose of peptide-vaccinated and mock-vaccinated mice after IBV infection. Days 5 (n = 5) and 6 (n = 5) were assessed in an independent experiment to day 7 (n = 4-5). f,g, Cytokine responses in the BAL on day 7 after IBV challenge (n = 4-5). Throughout the figure, means and s.e.m. are shown (n = 5 mice per group, except from mock group day 7 where n = 4). Data from days 6 and 7 are from two independent experiments. For c,d, statistical significance was determined using a two-way analysis of variance (Sidak's multiple comparisons). c, **P = 0.002; d, **P = 0.0014, *P = 0.016. For e-g, statistical significance was determined using an unpaired two-tailed t-test. e, Lung, *P = 0.016, **P = 0.005; nose, **P = 0.0076; g,*P = 0.0038, # P = 0.024, **P = 0.0075.
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ICV infection. HHD-A2 mice express a chimeric MHC-I monochain comprising human β2-microglobulin covalently linked to the HLA-A*02:01 α1 and α2 domains, and murine α3 and transmembrane domains 39 , and thus can respond to many human HLA-A*02:01-restricted epitopes, including IAV-derived A2-M 158 (ref. 38 ) and cancer-derived A2-WT1A neoantigen 40 . These mice are not confounded by infection history or coexpression of other MHC-I molecules and provide a tool for understanding influenzaspecific CD8
+ T cells in vivo and determining their protective role in influenza.
To verify the immunogenicity of novel IBV-derived peptides, we infected HHD-A2 mice intranasally with B/Malaysia. On day 10 after infection, we stimulated splenocytes with the 67 novel IBV peptides individually and measured IFN-γ and ΤΝF production. As in humans (Fig. 2h) , CD8
+ T cell responses were targeted towards A2-BHA 543-551 (mean 5% of CD8 + T cells) and A2-BNS1 266-274 (mean 1.8%), with smaller responses observed for A2-BHA 538-551 and A2-BNS1 264-274 (mean <0.5%), which overlap with A2-BHA 543-551 and A2-BNS1 266-274 , respectively (Fig. 6a,b) . We also assayed six pools of 10-12 peptides, as for humans (Supplementary Table 2) , and assessed CD8 + T cells to those at the site of infection (bronchoalveolar lavage, BAL). CD8
+ T cell responses were targeted to pools 2 and 3, which contained the BHA 543-551 , BNS1 266-274 and BNS1 264-274 peptides, as confirmed separately (Fig. 6c,d) .
To compare primary CD8 + T cells directed at BHA 543-551 and BNS1 266-274 epitopes with secondary responses, we primed HHD-A2 mice intranasally with B/Malaysia, and then intranasally infected them with the heterologous strain B/Phuket 6 weeks later ( Supplementary Fig. 7b,c) . Assessment of CD8 + T cell responses against the main A2-BHA 543-551 and A2-BNS1 266-274 epitopes on day 8 after challenge showed that the number of secondary IFN-γ + TNF + CD8 + T cells in the spleen was ~27-fold higher than that after primary infection (Supplementary Fig. 7a) . Additionally, CD8
+ T cells for both specificities showed increased polyfunctionality (IFN-γ + TNF + IL-2 + ) after challenge (0.14 and 2.14%, respectively, for BHA 543 ) (Supplementary Fig. 7d ). Thus, using our model of IBV in HHD-A2 mice, we verified the novel (identified by immunopeptidomics) immunodominant IBV-specific A2-BHA 543-551 and A2-BNS1 266-274 epitopes in both primary and secondary IBV infections.
Lack of A2-PB1 413
+
CD8
+ T cells in HHD-A2 mice. As universal A2-PB1 413 +
+ T cells can be detected in both IAV-and IBVinfected subjects, we assessed A2-PB1 413 +
+ T cells after IAV (A/ X31), IBV (B/Malaysia) or ICV (C/Perth) infection of HHD-A2 mice. To our surprise, CD8 + T cells specific for the A2-PB1 413 epitope were not detected after (1) primary IAV, IBV or ICV infection ( Supplementary Fig. 8a ), (2) secondary infection with a heterologous virus (for example, A/X31→A/PR8) or a heterotypic virus (for example, A/X31→B/Mal) in all four possible combinations (A→A, A→B, B→B and B→A) ( Supplementary Fig. 8b) or (3) 
+ T cells in HHD-A2 mice were not detected after lipopeptide ( Supplementary  Fig. 8d) or peptide (Supplementary Fig. 8f ) vaccination or with tetramer enrichment in naive mice. Thus, the above experiments ( Supplementary Fig. 8 ) provide strong evidence for a lack of naive A2-PB1 413 -specific precursors in HHD-A2 mice, probably owing to a T cell antigen receptor (TCR) repertoire hole in HHD-A2 mice toward the A2-PB1 413 epitope. Hence, the protective role of universal A2-PB1 413 +
+ T cells toward IAV, IBV and ICV infection could not be assessed in HHD-A2 mice (Supplementary Note).
Protective capacity of BHA 543
+ and BNS1 266 + CD8 + T cells in HHD-A2 mice. Previous studies using CD8
+ T cell depletion in mice lacking antibodies have demonstrated a role for CD8 + T cells during IBV infection 41 . To determine the protective capacity of novel IBV-derived CD8 + T cell epitopes in HHD-A2 mice, we vaccinated mice with the BHA 543 and BNS1 266 peptides using a prime-boost approach, then infected mice intranasally with 5 × 10 3 plaque-forming units (p.f.u.) B/Malaysia (Fig. 7a) . On day 6 after boosting and before vaccination, numbers of innate cells (neutrophils, macrophages and γδ T cells) were comparable between mock (adjuvant alone) and peptide-adjuvant-vaccinated groups in blood (data not shown). Thus, any nonspecific inflammatory or innate effects of vaccination are controlled for in mock animals.
Vaccination with peptides led to significantly higher numbers of total A2-BHA 543 -and A2-BNS1 266 -tetramer +
CD8
+ T cells in the spleen on days 6 and 7 after IBV infection when compared to mock-vaccinated (adjuvant alone) mice (~5.6-fold) (Fig. 7b,c) . A2-BHA 543
+ and A2-BNS1 266 + CD8 + T cell numbers were comparable (P > 0.05) in the BAL (about two-fold increase in immunized mice). After immunization, however, there was an increase in recruitment of A2-BHA 543 +
+ T cells to the site of infection between days 6 and 7 (Fig. 7d) . Importantly, peptide-vaccinated mice exhibited significant protection against IBV, as shown by a significant ~65% reduction in viral titers in the lung and nose on day 6 and 100% clearance in the lung on day 7 after IBV infection when compared to the mock-immunized group (Fig. 7e) . Additionally, there was a significant decrease in inflammatory cytokines (MIP-1β, IL-6, IL-1β and IFN-γ) in day 7 BAL of peptide-vaccinated mice in comparison to mock-immunized animals (Fig. 7f,g ). Thus, CD8
+ T cells directed at our novel HLA-A2.1-restricted IBV-specific epitopes are protective, as they can markedly accelerate viral clearance and reduce the cytokine storm at the site of infection.
Discussion
Cytotoxic CD8
+ T cells have a crucial role in protection from severe influenza disease in humans and animal models of influenza virus infection 1, 2 . CD8
+ T cells limit viral replication and promote clearance of infected cells whose recognition depends on presentation of viral peptides by MHC-I molecules. High conservation of these peptides allows cross-recognition of distinct IAV strains, including pandemic and avian IAV viruses 1, 2 . Our study examines two levels of cross-reactivity by influenza-specific CD8 + T cells: (1) heterotypic cross-reactivity across IAV and IBV, and in some instances ICV, by CD8 + T cells recognizing peptides derived from conserved influenza regions, and (2) IBV-wide cross-reactivity by CD8 + T cells recognizing conserved IBV regions.
Broadly neutralizing antibodies to the IAV and/or IBV hemagglutinin stem are the focus of recent research. However, so far, such broadly cross-reactive antibodies are rare and immuno-subdominant compared to strain-specific antibodies to the variable hemagglutinin head 7 . Conversely, broadly cross-reactive CD8 + T cells are abundant at the population level, can be recruited in ~50% and ~80% of HLA-A*02:01-expressing individuals infected with IAV or IBV, respectively, and can account for substantial immune responses towards influenza. Thus, combining broadly neutralizing antibodies with broadly cross-reactive and abundant CD8 + T cells is important for optimal universal protection against distinct influenza strains. Cross-reactivity across IAV and IBV is unprecedented for CD8 + T cells and atypical for influenza-specific CD4
+ T cells and antibodies. Only one rare antibody (CR9114) cross-recognizing conserved IAV and IBV hemagglutinin stem regions has been reported 8 and its contribution to human infection remains unknown. Similarly, a highly conserved CD4 + T cell epitope containing a peptide from the hemagglutinin fusion peptide has been identified although it has been poorly characterized 42 . Universal memory A2-PB1 413 CD8 + T cells, however, are prominent in human blood and lung tissues, and emerge as activated effectors during human IAV and IBV. Additionally, such CD8
+ T cells were found in the majority (80%) of donors we tested, and thus are abundant across HLA-A*02:01 + Articles NATure ImmuNOLOgy donors. Furthermore, our reported heterotypic cross-reactivity, restricted by HLA-A*02:01, HLA-A*01:01 and HLA-B*37:01, covers ~54% of the world population.
The IBV-wide cross-reactivity resembles IAV-wide cross-reactivity provided by well-characterized CD8 + T cells, exemplified by A2-M1 58 (ref. 38 ). Although the ability of CD8 + T cells to cross-react across IBV lineages has been reported 11 , the antigenic specificity underpinning such cross-reactivity has been unknown. We identified CD8
+ T cell targets from BHA and BNS1 proteins and show that these responses are protective in mice. The observation that IBV-wide cross-reactivity can occur towards peptides derived from BHA is intriguing, as it contests the belief that CD8 + T cell crossreactivity is conferred by peptides from internal influenza proteins. Given the high prevalence of HLA-A*02:01 and the clinical significance of IBV, our work implies that CD8
+ T cell-targeting vaccines should be formulated with broader antigenic specificity not limited to NP and M1.
Here, we provide direct evidence for the role of CD8 + T cells in protection against IBVs, as demonstrated by immunization with our newly identified IBV peptides. After IBV infection, peptideimmunized mice displayed significant reduction in viral titers and inflammation when compared to mock-immunized animals. To our surprise, A2-PB1 413
+ T cells were undetectable in HHD-A2 mice, irrespective of the infection or immunization protocol. This indicates that HHD-A2 mice lack naive A2-PB1 413 +
CD8
+ TCR precursors, probably resulting from a TCR repertoire hole, consistent with previous studies in HHD-A2-DRB1 mice 43 . Although HHD-A2 mice express a chimeric MHC-I monochain comprising the human β2-microglobulin covalently linked to HLA-A*02:01 α1 and α2 domains and the murine α3 and transmembrane domains, TCRs remain murine. Thus, although HHD-A2.1-expressing mice respond to several human HLA-A*02:01-restricted epitopes 38, 40, 44 TCRs for others might be lacking. Although these mice are useful for screening peptides, such results should be validated in human samples. HHD mice are, however, important in assessing the protective capacity of HLA-A2-restricted CD8 + T cells. By vaccinating HHD-A2 mice and challenging them with IBV, we provide evidence for a protective role of CD8 + T cells in IBV infection after peptide vaccination, consistent with CD8 + T cell depletion in mice lacking B cells 41 . In conjunction with the activation of these CD8 + T cells in subjects and the presence of T RM cells in the human lung, our studies suggest that vaccinating against these epitopes could provide protection in humans.
The antigenic origin of broadly cross-reactive epitopes is of interest. PB1 is the most conserved protein across IAV and IBV, with ~60% amino acid identity, in contrast with 30% for other proteins 4, 24 . The PB1 413 peptide is derived from the most conserved protein region, motif B (residues 406-422 of IAV-PB1 protein), a core motif present in viral RNA-dependent polymerases. Genome-wide mutational analysis has demonstrated that IAV cannot tolerate substitutions in these motifs 45 . Notably, the IBV-wide cross-reactivity is conferred by the BHA 543 peptide, which is derived from the BHA stalk, which shows considerably higher conservation than the hemagglutinin head 46 . Mutagenesis screens have revealed limited tolerance to 15-nucleotide insertions in BHA, particularly in the stalk domain 46 . Thus, universally cross-reactive CD8 + T cells target epitopes with little sequence flexibility, making them ideal targets for universal and IBV-wide influenza vaccines.
The ability of CD8 + T cells to confer heterotypic cross-reactivity across IAV and IBV and the knowledge of cross-reactive epitopes across IAV and IBV types and within IBV strains have implications for the design of universal influenza vaccines that do not require annual reformulation. Pre-emptive influenza vaccines eliciting broadly cross-reactive and long-lasting CD8 + T cells would reduce annual rates of IAV-and IBV-induced morbidity and mortality globally. Additionally, influenza vaccines eliciting immunity across IAV, IBV and ICV could protect children from severe ICV disease 5 . Furthermore, T cell-targeted vaccines would augment numbers of universal IAV-, IBV-and ICV-specific CD8 + T cells and IAV-and IBV-specific CD8 + T cells in individuals with previous viral exposures and thus confer stronger protective immunity after infection 14 .
It is important to consider universal CD8
+ T cells alongside universal antibodies for the design of universally cross-reactive influenza vaccines, especially as current inactivated influenza vaccines do not elicit influenza-specific CD8 + T cell responses 19 .
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fractions were combined into nine pools, vacuum-concentrated and reconstituted in 12 µl 0.1% formic acid (Thermo Fisher Scientific). Reconstituted fraction pools were analyzed by LC-MS/MS using an information-dependent acquisition strategy on a Q-Exactive Plus Hybrid Quadrupole Orbitrap (Thermo Fisher Scientific) coupled to a Dionex UltiMate 3000 RSLCnano system (Thermo Fisher Scientific). 6 µl of concentrated material was loaded onto a Dionex Acclaim PepMap100 200-mm C18 Nano-Trap Column with 100-μm internal diameter (5-μm particle size, 300-Å pore size) in buffer A (2% acetonitrile, 0.1% formic acid) at a flow rate of 15 µl min -1 . Peptides were then separated by switching a Dionex Acclaim RSLC PepMap RSLC C18 column (50-cm length, 75-μm internal diameter, 2-μm particle size, 100-Å pore size) in line and eluting the peptides (250 nl min -1 ) over an increasing gradient of buffer B (80% acetonitrile, 0.1% formic acid) of 2.5-7.5% over 1 min, 7.5-35% over 40 min, 35-99% over 5 min, 99% over 6 min and returning to 2.5% buffer B over 1 min, before re-equilibration at 2% for 20 min. Data were collected in positive mode: MS1 resolution, 70,000; scan range, 375-1,800 m/z; MS2 resolution, 17,500; scan range, 200-2,000 m/z. The top 12 ions of +2 to +5 charge per cycle were chosen for MS/MS with a dynamic exclusion of 15 s. Raw files were converted to mgf format and spectra were searched against a proteome database consisting of the human proteome (UniProt/Swiss-Prot v2016_04), the B/Malaysia proteome and a sixreading frame translation of the B/Malaysia genome using ProteinPilot software (version 5.0, SCIEX), considering biological modifications and using a decoy database for false discovery rate analysis. Length distribution and motif analyses were based on human peptides assigned at confidences greater than that required for a 5% false discovery rate, precursor delta mass ≤ 0.05. Peptides assigned to the influenza proteome at any confidence were also considered, precursor delta mass ≤ 0.05. Probable HLA-A*02:01 binders were determined based on appearance across the experiments and antibodies (BB7.2 versus w632 and class II). Of the 73 ligands, 67 were chosen for synthesis in native form and used in subsequent analyses. Selected peptides met any of the following criteria: (1) identification in both experiments, (2) confidence of sequence assignment >50, (3) predicted halfmaximum inhibitory concentration (IC 50 ) of binding to HLA-A*02:01 <2,500 nM. The 12-mers to 14-mers were synthesized regardless of meeting these criteria. The HLA-A*02:01 binding predictions were made on 18.07.2018 using the Immune Epitope Database Analysis Resource ANN, also known as NetMHC (ver. 4.0), tool [54] [55] [56] . Peptide binding motifs were visualized using Icelogo software (static reference method against the SWISS-PROT human proteome) 57 .
Screening of novel peptide ligands. For in vivo screening, HHD mice were infected with 100 p.f.u. of B/Malaysia intranasally. On day 10, spleen and BAL were harvested and processed into single-cell suspensions. Lymphocytes were stimulated with 1 μM peptide in RF10 with 10 U ml -1 of recombinant human IL-2 for 5 h in the presence of brefeldin A (BD GolgiPlug). Cells were stained with panel 3 (Supplementary Table 10 ) and analyzed as described above. For in vitro screening, cryopreserved PBMCs from HLA-A*02:01 + healthy adults were expanded with peptide pools (final concentration of 10 μM). Responses against cognate pools were assessed on day 9-10. Any positive pools were further dissected by restimulating remaining cultures with individual peptides on day 11-12. Immunogenic peptides were validated by in vitro expansion with single peptide and ICS assay with the C1R-A2 cells pulsed with the cognate peptide.
Tetramer-associated magnetic enrichment of antigen-specific CD8
+ T cells. TAME was performed as described 29 . Briefly, cryopreserved PBMCs (1 × 10 6 to 50 × 10 6 ) were thawed, counted and incubated with anti-human FcR block (Miltenyi Biotec) before being stained with pMHC-I tetramers conjugated to PE-SA or APC-SA for 1 h at room temperature. Cells were washed, incubated with anti-PE or anti-APC MicroBeads (Miltenyi Biotec) and passed through a LS column (Miltenyi Biotec) according to the manufacturer's instructions. After magnetic enrichment, unenriched, flow-through and enriched samples were stained for surface and intracellular markers as described above. A limit of detection for TAME analysis was set at 10 -7 , as determined by Alanio et al 27 . Panels 4a and 4b were used (Supplementary Table 10 ). Lung samples were not enriched and were stained with panel 5.
Single-cell RNA-seq. Single tetramer + cells were sorted into 96-well plates containing 0.5 μl dNTP mix (10 mM), 0.5 μl oligo-dT primer (5 μM), and 1 μl lysis buffer (prepared by adding 1 μl RNase inhibitor to 19 μl Triton X-100 solution, 0.2% (v/v)). Libraries were prepared using the Smart-seq2 protocol as described 18, 58, 59 with the following modifications. cDNA synthesis and preamplification reaction volumes were halved to 5 and 12. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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